OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today announced U.S. Food and Drug Administration (FDA) clearance of its Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche's tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) and run on Roche's cobas® 5800, 6800, and 8800 molecular diagnostic systems.

GlobeNewsWire • Jun 11, 2026

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

OraSure Announces First Quarter 2026 Financial Results

BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026.

GlobeNewsWire • May 6, 2026

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026.

GlobeNewsWire • Apr 22, 2026

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D.

GlobeNewsWire • Apr 17, 2026

Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says

Activist investor Altai Capital Management called on OraSure Technologies ​to explore a sale, saying the medical device maker could fetch double its current share price, according to a letter ‌seen by Reuters.

Reuters • Mar 17, 2026

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital's March 17, 2026, letter: OraSure's Board and management team are steadfast in our commitment to driving value and acting in the best interests of all shareholders through disciplined execution and rigorous oversight.

GlobeNewsWire • Mar 17, 2026

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the “Board”) outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. In the letter, Altai calls on the OraSure.

Business Wire • Mar 17, 2026

OraSure Technologies, Inc. (OSUR) Q4 2025 Earnings Call Transcript

OraSure Technologies, Inc. (OSUR) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026

OraSure to Launch OraQuick™ HIV Self-Test in Canada

BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick™ HIV Self-Test has received a license from Health Canada for use in Canada.

GlobeNewsWire • Feb 10, 2026